A cost-utility analysis of interferon beta for multiple sclerosis
Parkin D, Miller P, McNamee P, Thomas S, Jacoby A, Bates D
Record ID 31999009898
English
Authors' objectives:
1. To identify to what extent IFBeta-1b generates quality of life (QOL) gains. 2. To measure and value QOL gains. 3. To assess the net costs to the health service and society associated with IFBeta-1b. 4. To compare net costs and QOL gains in a cost-utility model.
Authors' recommendations:
IFBeta-1b produces important occasional short-term gains in QOL to people with RRMS, but these translate into only small gains in QALYs overall. Even with optimistic estimates of longer-term gains the aggregate QALY gains are small. These benefits are achieved only with a large additional cost.
Authors' methods:
Cost study
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/987
Year Published:
1998
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Costs and Cost Analysis
- Interferon-beta
- Multiple Sclerosis
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.